1.72
-0.04 (-2.27%)
| Penutupan Terdahulu | 1.76 |
| Buka | 1.77 |
| Jumlah Dagangan | 5,810,400 |
| Purata Dagangan (3B) | 5,073,444 |
| Modal Pasaran | 2,385,017,856 |
| Harga / Jualan (P/S) | 1.24 |
| Harga / Buku (P/B) | 4.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Mar 2025 |
| Margin Operasi (TTM) | 1,905.89% |
| EPS Cair (TTM) | -0.190 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -28.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 250.00% |
| Nisbah Semasa (MRQ) | 0.910 |
| Aliran Tunai Operasi (OCF TTM) | -130.80 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -176.40 M |
| Pulangan Atas Aset (ROA TTM) | -12.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | SINOMAB BIO-B | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| SINOMAB BIO-B | 2 B | - | - | 4.23 |
| CSTONE PHARMA-B | 14 B | - | - | 27.87 |
| CKLIFE SCIENCES | 7 B | - | - | 1.88 |
| VIVA BIOTECH | 4 B | - | 28.57 | 0.940 |
| ANTENGENE-B | 3 B | - | - | 2.84 |
| IMMUNOTECH-B | 2 B | - | - | 20.15 |
|
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.32% |
| % Dimiliki oleh Institusi | 12.48% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |